



MT2024-12: A Phase 1 Study Evaluating BAFFR-targeting CAR T cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over This study is NOT accepting healthy

volunteers

Inclusion Criteria:

- able to do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - diagnosis of Large B-cell lymphoma (LBCL) or Mantle Cell Lymphoma (MCL) - cancer has recurred or not responded to at least 2 prior lines of treatment - willing to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of medication - see link to clinicaltrials.gov for complete inclusion & exclusion criteria

Exclusion Criteria:

- prior allogeneic stem cell transplant - Autologous stem cell transplant within 6 months - Auto-immune disease or condition requiring systemic immunosuppressant therapy, including uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP) - significant cardiac disease including heart failure or arrhythmia - history of a stroke in the past 6 months - history of another active cancer in the past 3 years - women who are pregnant or breast feeding

Conditions & Interventions

Interventions:

Biological: BAFFR-CAR T cells

Conditions:
Cancer
Keywords:

LBLC, Mantle Cell Lymphoma (MCL), Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

More Information

Description: The purpose of this study is to assess the safety of administering BAFFR-CAR T cells in participants with relapsed or refractory (r/r) B- cell non-Hodgkin lymphoma (B-NHL). We also will determine the maximum tolerated dose (MTD)/RP2D of BAFFR-CART cells.

Study Contact: Marie Hu - hu000322@umn.edu **Principal Investigator:** Veronika Bachanova, MD

Phase: PHASE1

IRB

Number: STUDY00022432

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.